Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: Results of a pharmacokinetic/pharmacodynamic meta-analysis Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Indoles
  • Neoplasms
  • Pyrroles

abstract

  • The results of this meta-analysis indicate that increased exposure to sunitinib is associated with improved clinical outcomes (longer TTP, longer OS, greater chance of antitumor response), as well as some increased risk of adverse effects. A sunitinib 50-mg starting dose seems reasonable, providing clinical benefit with acceptably low risk of adverse events.

publication date

  • July 2010

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s00280-009-1170-y

PubMed ID

  • 19967539

Additional Document Info

start page

  • 357

end page

  • 71

volume

  • 66

number

  • 2